CT imaging features of 4121 patients with COVID-19 (search done: 16 March 2020)

Added June 2, 2020

Citation: Zhu J, Zhong Z, Li H, et al. CT imaging features of 4121 patients with COVID-19: a meta-analysis. Journal of Medical Virology 2020; [ePub ahead of print: 21 April 2020]

What is this? COVID-19 is a novel infection and research around diagnostic features is important for clinicians. In particular, information on common computed tomography (CT) findings may be helpful.

In this rapid review and meta-analysis, the authors searched for observational studies examining CT imaging features of COVID-19 patients. They did not restrict by language of publication and searched for articles published between 1 January 2020 and 16 March 2020. They identified 34 studies from China (4121 patients), which were included in the meta-analyses for different imaging features.

What was found: In the studies included in this review, bilateral lung involvement and multi-lobar involvement were common findings on CT imaging (74% and 67%, respectively).

In the studies included in this review, single lung and/or lobe involvement and normal findings on CT imaging were rare for patients with COVID-19 infection, with 8.4% of COVID-19 patients having normal CT findings.

In the studies included in this review, ground-glass opacities were the most common lesion sign observed (68%) and air bronchograms, “crazy-paving” pattern and consolidation were also common.

In the studies included in this review, accompanying clinical signs were less common: 27% of patients had signs of pleural thickening.

It is uncertain whether particular stages of COVID-19 infection have characteristic CT findings.

 

Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.

Share